Medical treatment of hypertrophic cardiomyopathy

Current Cardiology Reports

Volumn 2, Issue 2, 2000, Pages 148-153

  Sherrid, Mark V ^a   Gunsburg, David ^a   Sharma, Ajay ^a  

^a Division of Cardiology ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARDIOTONIC AGENT;

ANIMAL; DISEASE MODEL; DOPPLER FLOWMETRY; ECHOGRAPHY; HEART ARRHYTHMIA; HEART LEFT VENTRICLE HYPERTROPHY; HUMAN; HYPERTROPHIC CARDIOMYOPATHY; PATHOPHYSIOLOGY; REVIEW;

ANIMALS; ARRHYTHMIA; CARDIOMYOPATHY, HYPERTROPHIC; CARDIOTONIC AGENTS; DISEASE MODELS, ANIMAL; HUMANS; HYPERTROPHY, LEFT VENTRICULAR; ULTRASONOGRAPHY, DOPPLER;

EID: 0034151874     PISSN: 15233782     EISSN: 15343170     Source Type: Journal    
DOI: 10.1007/s11886-000-0012-7     Document Type: Article

References (26)

1. Maron BJ, Bonow RO, Cannon RO, et al. : Hypertrophic cardiomyopathy- interrelations of clinical manifestations, pathophysiology and therapy. N Engl J Med 1987, 316:844-852.
2. Wigle ED, Rakowski H, Kimball BP, William WG: Hypertrophic cardiomyopathy-clinical spectrum and treatment. Circulation 1995, 92:1680-1692.
3. Spirito P, Seidman CE, McKenna WJ, Maron BJ: The management of hypertrophic cardiomyopathy. N Engl J Med 1997, 336, 11:775-785.
4. Lele SS, Thomson HL, Seo H, et al. : Exercise capacity in hypertrophic cardiomyopathy. Role of stroke volume limitation, heart rate and diastolic filling characteristics. Circulation 1995, 92:2886-2894.
5. Klues HG, Maron BJ, Dollar AL, Roberts WC: Diversity of structural mitral valve alterations in hypertrophic cardiomyopathy. Circulation 1992, 85:1651-1660.
6. Shah PM, Taylor RD, Wong M: Abnormal mitral valve coaptation in hypertrophic obstructive cardiomyopathy: proposed role in SAM of mitral valve. Am J Cardiol 1981, 48:258-262.
7. Jiang L, Levine RA, King ME, Weyman AE: An integrated mechanism for SAM of the mitral valve in hypertrophic cardiomyopathy based on echocardiographic observations. Am Heart J 1987, 113:633-644.
8. Sherrid MV, Chu CK, DeLia E, et al. : An echocardiographic study of the fluid mechanics of obstruction in hypertrophic cardiomyopathy. J Am Coll Cardiol 1993, 22:816-825.
9. Pollick C: Muscular subaortic stenosis: hemodynamic and clinical improvement after disopyramide. N Engl J Med 1982, 307:997-999.
10. Sherrid M, DeLia E, Dwyer E: Oral disopyramide therapy for obstructive hypertrophic cardiomyopathy. Am J Cardiol 1988, 62:1085-1088.
11. Pollick C: Disopyramide in hypertrophic cardiomyopathy. Noninvasive assessment after oral administration. Am J Cardiol 1988, 62:1252-1255.
12. Hongo M, Nakatsuka T, Takenaka H, et al. : Effects of intravenous disopyramide on coronary hemodynamics and vasodilator reserve in hypertrophic obstructive cardiomyopathy. Cardiology 1996, 87:6-11.
13. Niki K, Sugawara M, Asano R, et al. : Disopyramide improves the balance between myocardial oxygen supply and demand in patients with hypertrophic obstructive cardiomyopathy. Heart Vessels 1997, 12:111-118.
14. Tokudome T, Mizushige K, Ueda T, et al. : Effect of disopyramide on left ventricular pressure gradient in hypertrophic obstructive cardiomyopathy in comparison with propranolol-a case report. Angiology 1999, 50:331-335.
15. Rosing DR, Kent KM, Borer JS, et al. : Verapamil therapy: New approach to the pharmacologic treatment of hypertrophic cardiomyopathy. I. Hemodynamic effects. Circulation 1979, 60:1201-1207.
16. Rosing DR, Kent KM, Maron BJ, Epstein SE: Verapamil therapy: A new approach to the pharmacologic treatment of hypertrophic cardiomyopathy: II: Effects on exercise capacity and symptomatic status. Circulation 1979, 60:1208-1213.
17. Epstein SE, Rosing DR: Verapamil: its potential for causing serious complications in patients with hypertrophic cardiomyopathy. Circulation 1981, 64:437-441.
18. Hamada M, Shigematzu Y, Ikeda S, et al. : Class Ia antiarrhythmic drug cibenzoline: a new approach to the medical treatment of hypertrophic obstructive cardiomyopathy. Circulation 1997, 96:1520-1524.
19. Sherrid MV, Pearle G, Gunsburg D. The mechanism of benefit of negative inotropes in obstructive hypertrophic cardiomyopathy. Circulation 1998, 97:41-47.
20. Kyriakidis M, Triposkiadis F, Dernellis J, et al. : Effects of cardiac versus circulatory angiotensin-converting enzyme inhibition on left ventricular diastolic function and coronary blood flow in hypertrophic obstructive cardiomyopathy. Circulation 1998, 97:1342-1347.
21. Dilsiziam, V, Bonow RO, Epstein SE, Fananapazir L: Myocardial ischemia detected by thallium scintigraphy is frequently related to cardiac arrest and syncope in young patients with hypertrophic cardiomyopathy. J Am Coll Cardiol 1993, 22:796-804.
22. Sugihara H, Taniguchi Y, Ito K, et al. : Effects of diltazem on myocardial perfusion abnormalities during exercise in patients with hypertrophic cardiomyopathy. Ann Nucl Med 1998, 12:349-354.
23. Sussman MA, Lim HW, Gude N, et al. : Prevention of cardiac hypertrophy in mice by calcineurin inhibition. Science 1998, 281:1690-1693.
24. Demirtas E, Sag C, Kursaklioglu H, et al. : Effects of octreotide in patients with hypertrophic obstructive cardiomyopathy. Jpn Heart J 1998, 39:173-181.
25. Hartmann A, Putz A, Hopf R: Effect of long-term ACEinhibitor therapy in hypertrophic cardiomyopathy (HCM) [abstract]. JACC 1995:234-A.
26. Prasad K, Frenneaux PK: Hypertrophic cardiomyopathy: is there a role for amiodarone? Heart 1998, 79:317-318.